The H3antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers
British Journal of Clinical Pharmacology2013Vol. 77(6), pp. 965–974
Citations Over Time
Abstract
ABT-288 was tolerated at a 15-fold higher dose and 12-fold higher exposures in subjects with schizophrenia than previously observed in healthy volunteers. The greater ABT-288 tolerability was not due to limited brain uptake.
Related Papers
- → Pharmacokinetics and tolerability of SRT2104, a first‐in‐class small molecule activator of SIRT1, after single and repeated oral administration in man(2012)124 cited
- → Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV(2021)43 cited
- → <p>A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson&rsquo;s disease, in healthy volunteers</p>(2019)20 cited
- → Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects(2013)17 cited
- → Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers(2013)3 cited